周末

1. Moore RS, Xiong R, Astacio E, et al. (2026).Gut-derived serine protease reduces sleep but extends lifespan.bioRxiv2026.06.25.734557.

2.Barros J, Ferrini L, Maio M, et al. (2026).Lipid-mediated GPR32 signaling reprograms macrophage metabolism to impair anti-tuberculous immunity.bioRxiv2025.07.07.663524.

3.Byrne EM, Di Vicino U, Farah N, et al. (2026).Retinal resuscitation in post-mortem eyes.bioRxiv2026.06.25.733416.

4.Zhang X, Kvamme T, Nagai Y, Silvanto J. (2026).How the Body Shapes the Mind's Eye Cardiac vagal reactivity predicts visual imagery vividness.bioRxiv2026.05.12.724726.

1.Lin K, Pappas TN, Moris DP, Flum DR.  (2026). Operative versus Nonoperative Management for Appendicitis.New EnglandJournal ofMedicine395:86–89.

2.McDermott DH, Calderon-Perez R, Ormiston Z, et al.(2026). Somatic Genetic Rescue of Immunodeficiency in WHIM Syndrome.New EnglandJournal ofMedicine395:96–98.

3.Huang S, Kim YJ, Cao X, et al.(2026). Phosphatidylserine and RhoB connect PI4P and PA metabolism to maintain plasma membrane identity.Journal ofCellBiology225:e202509213.

4.Kuranda K, Gross DA, Ronzitti G.(2026). Promises of co-stimulatory inhibition for durable and repeatable AAV gene therapy.MolecularTherapy34:3725–3726.

5.MA, Kumi GS, Chapman MS.  (2026). Modulating receptor interactions in retargeted AAV vectors.MolecularTherapy34:3727–3728.

6.Hu HM, Han Y, Li Y.(2026). Early evidence of the efficacy of TCR-T therapy targeting the G12V mutation in patients with advanced pancreatic cancer.MolecularTherapy34:3738–3739.

7.Xu X, Gu H, Cha Z, et al.(2026). T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial.MolecularTherapy34:4001–4020.

8.Song C, Liu J, Wang Q, et al. (2026). Challenging the more-is-better dogma: A precision-optimized AAV gene therapy for SMA.MolecularTherapy34:3783–3804.

9.Xicluna R, Yamada K, Gonzalez-Visiedos M, et al.(2026). Transient prophylactic immunosuppression with abatacept or dasatinib prevents immune responses in AAV gene transfer.MolecularTherapy34:3805–3819.

10.Brittain TJ, Jang S, Coughlin GM, et al.(2026). Structural basis of liver de-targeting and neuronal tropism of CNS-targeted AAV capsids.Molecular Therapy34:3820-3837.

11.Andres-Mateos E, Kozlowski C, Zhang H, et al.(2026). Laterally spreading AAV.SPR enables safe and efficient RS1 delivery to the macula after peripheral subretinal injection.MolecularTherapy34:3838–3853.

12.Chen XJ, Blanco-Elorrieta E.(2026). A Shared Neural Mechanism for Abstract Grammatical Computations across Languages in Bilinguals.Journal ofNeuroscience46:e2341252026.

13.Etxeberria A, Lee SH, Kuhn JA, et al.  (2026). Microglia-mediated protection against Alzheimer's disease pathology and detrimental effects in white matter revealed byPtpn6deletion.Neuron114:2367–2385.e8.

14.Downie I, Szyszka P, Hall N, Edwards T. (2026).Evidence that Dogs Can Use Temporal Difference in Odorant Arrival to Discriminate Odorant Mixtures.bioRxiv2026.06.26.734637.

15.Gere-Becker M, Funk L, Groeger M, et al. (2026).A High-Affinity Nanobody Recognizing mNeonGreen Enables Versatile Biochemical, Cellular, andin vivoApplications.bioRxiv2026.06.30.735531.